The Solana trading platform said the deal closed at current market price with ParaFi committing to an extended token lockup. The post Jupiter Announces $35M ParaFiThe Solana trading platform said the deal closed at current market price with ParaFi committing to an extended token lockup. The post Jupiter Announces $35M ParaFi

Jupiter Announces $35M ParaFi Investment, Deal to Settle in JupUSD

2026/02/02 16:45
2 min read

Jupiter JUP $0.18 24h volatility: 1.3% Market cap: $598.29 M Vol. 24h: $60.94 M , a Solana-based SOL $101.9 24h volatility: 3.5% Market cap: $57.60 B Vol. 24h: $8.81 B decentralized exchange aggregator, announced on Feb. 2 a $35 million investment in its JUP token from ParaFi Capital. The deal will be settled entirely in JupUSD, Jupiter’s stablecoin.

According to Jupiter’s announcement, the deal closed at current market price with ParaFi committing to an extended token lockup.

Jupiter did not disclose the specific lockup duration. ParaFi Capital had not issued a public statement confirming the investment at the time of publication.

JupUSD to Settle $35M Transaction

JupUSD launched in January 2026 and will be used to settle the entire $35 million transaction. The stablecoin currently has a market cap of approximately $38.7 million, according to rwa.xyz data.

The deal nearly doubles JupUSD’s circulating supply.

JupUSD is backed primarily by USDtb, a stablecoin with approximately $859 million in circulation that is collateralized by BlackRock’s BUIDL tokenized treasury fund.

Jupiter developed JupUSD in partnership with Ethena Labs. ParaFi is also an existing investor in Ethena ENA $0.14 24h volatility: 3.0% Market cap: $1.08 B Vol. 24h: $206.35 M .

ParaFi Capital manages approximately $1.4 billion in assets and was founded in 2018.

The firm’s portfolio includes multiple Solana SOL $101.9 24h volatility: 3.5% Market cap: $57.60 B Vol. 24h: $8.81 B ecosystem investments such as SOL Strategies, Kamino, and Metaplex.

In January 2025, ParaFi invested CAD $27.5 million in Sol Strategies, a company focused on Solana network infrastructure.

Ryan Navi, Managing Director at ParaFi Capital, described that investment as supporting Sol Strategies’ mission to build critical infrastructure for the Solana network.

Jupiter’s Market Position

JUP/USD 15-minute chart showing price action on Feb. 1-2, 2026. The token traded between $0.17 and $0.19 over the period, with a recent price at $0.1873. | Source: GeckoTerminal/Meteora

JUP/USD 15-minute chart showing price action on Feb. 1-2, 2026. The token traded between $0.17 and $0.19 over the period, with a recent price at $0.1873. | Source: GeckoTerminal/Meteora

Jupiter processes over 90% of aggregator volume on Solana. The platform announced in June 2025 that cumulative trading volume had surpassed $1 trillion.

Coinbase integrated Jupiter’s trading technology in January 2026.

JUP trades at approximately $0.19 with a market cap of $596.6 million. The token is down roughly 91% from its all-time high of $2.00 reached in January 2024.

next

The post Jupiter Announces $35M ParaFi Investment, Deal to Settle in JupUSD appeared first on Coinspeaker.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26